Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Article 2020 en
Authors
EK
Efstathios Kastritis
XL
Xavier Leleu
BA
Bertrand Arnulf
Abstract
1 min read
BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis.
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, Elena Zamagni, Peter Mollee, María Teresa Cibeira, Stefan Schönland, Philippe Moreau, Roman Hájek, Arnaud Jaccard, Emmanuelle Nicolas‐Virelizier, Robin Filshie, Bradley Augustson, María‐Victoria Mateos, Paolo Milani, Meletios A Dimopoulos, É. Hachulla, Jean‐Paul Fermand, Andrea Foli, Antonio Palumbo, Pieter Sonneveld, Hans Erik Johnsen, Giampaolo Merlini, Giovanni Palladini
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, Elena Zamagni, María Teresa Cibeira, Fiona Kwok, Peter Mollee, Roman Hájek, Philippe Moreau, Arnaud Jaccard, Stefan Schönland, Robin Filshie, Emmanuelle Nicolas‐Virelizier, Bradley Augustson, María‐Victoria Mateos, Ashutosh Wechalekar, É. Hachulla, Paolo Milani, Meletios A Dimopoulos, Jean‐Paul Fermand, Andrea Foli,
Efstathios Kastritis, Ashutosh Wechalekar, Meletios A Dimopoulos, Giampaolo Merlini, Philip N. Hawkins, Vittorio Perfetti, Julian D. Gillmore, Giovanni Palladini
Discussion(0)
No comments yet. Be the first to comment.